Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer.

By V. Subbiah, R. Kreitman, Z. Wainberg, J. Cho, Jan H. M. Schellens, J. Soria, P. Wen, C. Zielinski, M. Cabanillas, G. Urbanowitz and 4 more. Journal of Clinical Oncology, 2018

745 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Molecular Biology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/5f0224f35a8903139c56ea3f9205383545583336

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. Sebastiano Filetti
2. D. Hartl
3. S. Leboulleux
4. L. Locati
5. K. Newbold
6. Mauro Papotti
7. C. Durante
8. A. Berruti

Citations in the corpus

• Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2019, background): “The ORR was 69% (11/16; 95% CI 41%–89%), and the treatment was well tolerated [139].”